

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/714,078
				Filing Date	November 14, 2003
				First Named Inventor	Gunars Valkirs
				Art Unit	1641
				Examiner Name	Lisa V. Cook
Sheet	1	Of	7	Attorney Docket Number	36671-743.503

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US 2002/0052000 A1	05/02/2002	Parthasarathy et al.	
	2.	US 2002/0106708 A1	08/08/2002	Thomas et al.	
	3.	US 2003/0119064 A1	06/26/2003	Valkirs et al.	
	4.	US 2003/0199000 A1	10/23/2003	Valkirs et al.	
	5.	US 2003/0211544 A1	11/13/2003	Buechler et al.	
	6.	US 2003/0219734 A1	11/27/2003	Buechler	
	7.	US 2004/0121343 A1	06/24/2004	Buechler et al.	
	8.	US 2004/0121350 A1	06/24/2004	Anderberg et al.	
	9.	US 2004/0126767 A1	07/01/2004	Anderberg et al.	
	10.	US 2004/0171064 A1	09/02/2004	Dahlen et al.	
	11.	US 2004/0176914 A1	09/09/2004	Buechler et al.	
	12.	US 2004/0203083 A1	10/14/2004	Buechler et al.	
	13.	US 2004/0209307 A1	10/21/2004	Valkirs et al.	
	14.	US 2004/0253637 A1	12/16/2004	Buechler et al.	
	15.	US 2005/0148024 A1	07/07/2005	Buechler	
	16.	US 2005/0164317 A1	07/28/2005	Buechler et al.	
	17.	US 2005/0255484 A1	11/17/2005	Valkirs et al.	
	18.	US 2006/0051825 A1	03/09/2006	Buechler et al.	
	19.	US 2006/0105419 A1	05/18/2006	Blankenberg et al.	
	20.	US 2007/0092911 A1	04/26/2007	Buechler et al.	
	21.	US 2007/0196880 A1	08/23/2007	Buechler et al.	
	22.	US 2007/0218498 A1	09/20/2007	Buechler et al.	
	23.	US 2007/0224643 A1	09/27/2007	Mcpherson et al.	
	24.	US 2007/0269836 A1	11/22/2007	Mcpherson	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST .3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/714,078
				Filing Date	November 14, 2003
				First Named Inventor	Gunars Valkirs
				Art Unit	1641
				Examiner Name	Lisa V. Cook
Sheet	2	Of	7	Attorney Docket Number	36671-743.503

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	25.	US 2008/0045444 A1	02/21/2008	Whittaker	
	26.	US 2008/0118924 A1	05/22/2008	Buechler	
	27.	US 4,900,662	02/13/1990	Shah et al.	
	28.	US 5,202,234	04/13/1993	Shah et al.	
	29.	US 5,382,515	01/17/1995	Shah et al.	
	30.	US 5,382,522	01/17/1995	Shah et al.	
	31.	US 5,482,935	01/09/1996	Adelman et al.	
	32.	US 5,683,885	11/04/1997	Kieback	
	33.	US 5,795,725	08/18/1998	Buechler et al.	
	34.	US 5,814,462	09/29/1998	Weinberger	
	35.	US 5,843,690	12/01/1998	Gargan	
	36.	US 6,156,521	12/05/2000	Buechler et al.	
	37.	US 6,174,686 B1	01/16/2001	Buechler et al.	
	38.	US 6,495,519 B1	12/17/2002	He et al.	
	39.	US 6,579,687 B1	06/17/2003	Buechler et al.	
	40.	US 6,627,404 B1	09/30/2003	Buechler et al.	
	41.	US 6,939,678 B1	09/06/2005	Buechler et al.	
	42.	US 6,991,907 B1	01/31/2006	Buechler et al.	
	43.	US 7,341,838 B2	03/11/2008	Buechler et al.	
	44.	US 7,358,055 B2	04/15/2008	Valkirs et al.	
	45.	US 7,361,473 B2	04/22/2008	Valkirs et al.	
	46.	US 7,427,490 B2	08/20/2002	Valkirs	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/714,078	
				Filing Date	November 14, 2003	
				First Named Inventor	Gunars Valkirs	
				Art Unit	1641	
				Examiner Name	Lisa V. Cook	
Sheet	3	Of	7	Attorney Docket Number		36671-743.503

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> - Number <sup>3</sup> - Kind Code <sup>4</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	47.	WO 1998/043630 A1	08/10/1998	Ridker et al.		
	48.	WO 2001/042793 A2	06/14/2001	Hochstrasser et al.		
	49.	WO 2004/058055 A2	07/15/2004	Anderberg et al.		
	50.	WO 2004/094459 A2	11/04/2004	Buechler		
	51.	WO 2004/094460 A2	11/04/2004	Buechler et al.		

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	52.	ANDERSON, L. Candidate-Based Proteomics in the Search for Biomarkers of Cardiovascular Disease. J. Physiol. 563.1; 2004: 23-60.
	53.	BARBER, et al. Hemostatic function and progressing ischemic stroke: D-dimer predicts early clinical progression. Stroke. 2004 Jun;35(6):1421-5. Epub 2004 Apr 8.
	54.	BIDZSERANOVA, et al. Structure-activity studies on the effects of atrial natriuretic peptide, brain natriuretic peptide and their analogs on fear-motivated learning behavior in rats. Neuropeptides. 1992;23(2): 61-65.
	55.	BREYER, J. dissenting. Supreme Court of The United States, No. 04-607. Laboratory Coproration of America Holdings, DBA Labcorp, Petitioner v. Metabolite Laboratories, Inc., et al. June 22, 2006 (slip opinion) pages 1-15.
	56.	CARVILLE, et al. Thrombus precursor protein (TpPTM): marker of thrombosis early in the pathogenesis of myocardial infarction. Clin. Chem. 1996;42:1537-1541.
	57.	CHANG, et al. C-Reactive Protein Binds to Both Oxidized LDL and Apototic Cells Through Recognition of a Common Ligand: Phosphorylcholine of Oxidized Phospholipids.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/714,078
				Filing Date	November 14, 2003
				First Named Inventor	Gunars Valkirs
				Art Unit	1641
				Examiner Name	Lisa V. Cook
Sheet	4	Of	7	Attorney Docket Number	36671-743.503

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	58.	CHOUDHRI, et al. Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage. J Exp Med. 1999 Jul 5;190(1):91-9.
	59.	CHRISTENSON, et al. Standardization of cardiac troponin I assays: round Robin of ten candidate reference materials. Clin Chem. 2001 Mar;47(3):431-7.
	60.	CLARK, et al. Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia. Neurosci Lett. 1997 Nov 28;238(1-2):53-6.
	61.	COEROLI, et al. Nitric oxide production and perivascular tyrosine nitration following focal ischemia in neonatal rat. J Neurochem. 1998 Jun;70(6):2516-25.
	62.	COSSINS, et al. Enhanced Expression of MMP-7 and MMP-9 in Demyelinating Multiple Sclerosis Lesions. Acta. Neuropathol. 1997;94:590-598.
	63.	DE MEESTER, et al. In vivo inhibition of dipeptidyl peptidase IV activity by pro-pro-diphenyl-phosphonate (Prodipine). Biochem Pharmacol. 1997 Jul 1;54(1):173-9.
	64.	EIKELBOOM, et al. C-reactive protein in ischemic stroke and its etiologic subtypes. J Stroke Cerebrovasc Dis. 2003 Mar-Apr;12(2):74-81.
	65.	FASSBENDER, et al. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: kinetics of secretion and relation to the extent of brain damage and outcome of disease. J Neurol Sci. 1994 Apr;122(2):135-9.
	66.	FUKUI, et al. Focal Brain Edema and Natriuretic Peptides in Patients with Subarachnoid Hemorrhage. J. of Clin. Neuroscience. 2004;11(5): 507-511.
	67.	HARRINGTON, J.R. The Role of MCP-1 in Atherosclerosis. Stem Cells. 2000;18: 65-66.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>		
				Application Number	10/714,078	
				Filing Date	November 14, 2003	
				First Named Inventor	Gunars Valkirs	
				Art Unit	1641	
				Examiner Name	Lisa V. Cook	
Sheet	5	Of	7	Attorney Docket Number		36671-743.503

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	68.	HATFIELD, et al. CSF neuron-specific enolase as a quantitative marker of neuronal damage in a rat stroke model. Brain Res. 1992 Apr 17;577(2):249-52. (abstract only)
	69.	HEESCHEN, et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. The Lancet. 2000;354: 261-272.
	70.	International Search Report and the Written Opinion of the International Searching Authority dated 07/03/2008 from PCT Application No. US05/38225.
	71.	International Search Report dated 10/20/2004 for PCT Application No. US04/26984.
	72.	KANEKO, et al., Circulating levels of $\beta$ -chemokines in systemic lupus erythematosus. J. Rheumatol. 26:568-573, 1999.
	73.	KLINE, et al. New diagnostic tests for pulmonary embolism. Ann Emerg Med. 2000 Feb;35(2):168-80.
	74.	LESCUYER, et al. Identification of Post-Mortem Cerebral Spinal Fluid Proteins as Potential Biomarkers of Ischemia and Neurodegeneration. Proteomics. 2004;(4): 2234-2241.
	75.	LINDON, J. C. Biomarkers: Present concepts and future promise. Preclinica. 2003;1: 221.
	76.	LIP, et al. Von Willebrand Factor and Its Relevance to Cardiovascular Disorders. Br Heart J. 1995;74:580-583.
	77.	MA, et al. RAGE is expressed in pyramidal cells of the hippocampus following moderate hypoxic-ischemic brain injury in rats. Brain Res. 2003 Mar 21;966(2):167-74.
	78.	Management of the patient with stroke. Chapter One - Trends in stroke prevention and management. Available at: <a href="http://69.3.158.146/nurse/courses/nurseweek/NW0200/c1/p01.htm">http://69.3.158.146/nurse/courses/nurseweek/NW0200/c1/p01.htm</a>

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/714,078
				Filing Date	November 14, 2003
				First Named Inventor	Gunars Valkirs
				Art Unit	1641
				Examiner Name	Lisa V. Cook
Sheet	6	Of	7	Attorney Docket Number	36671-743.503

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	79.	McGIRT, et al. Serum Von Willebrand Factor, Matrix Metalloproteinase-9 and Vascular Endothelial Growth Factor Levels Predict the Onset of Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage. Neurosurgery. 2002;51(5):1128-1135.
	80.	Office Action from Japanese Patent Office dated 06/10/2008 for Japanese Application No. JP2003-521366 (in Japanese with English translation).
	81.	ORBE, et al. Independent association of matrix metalloproteinase-10, cardiovascular risk factors and subclinical atherosclerosis. Journal of Thrombosis and Haemostasis 2007;5 (1) , 91-97.
	82.	RUS, et al. Interleukin-6 and Interleukin-8 protein and Gene Expression in Human Arterial Atherosclerotic Wall. Atherosclerosis. 1996;127:263-271.
	83.	SHIRASAKI, et al. Serum S-100b protein as a biomarker for the assessment of neuroprotectants. Brain Res. 2004 Sep 24;1021(2):159-66.
	84.	STANEK, et al. Prognostic Evaluation of Neurohumoral Plasma Levels Before and During Beta Blocker Therapy in Advanced Left Ventricular Dysfunction. JACC. 2002;38(2): 436-442.
	85.	TAKEBAYASHI, et al. Association between circulating monocyte chemoattractant protein-1 and urinary albumin excretion in nonobese Type 2 diabetic patients. J Diabetes Complications. 2006 Mar-Apr;20(2):98-104.
	86.	TOMIDA, et al. Plasma concentrations of brain natriuretic peptide in patients with subarachnoid hemorrhage. Stroke. 1998 Aug;29(8):1584-7.
	87.	UCHIYAMA et al., Alterations of platelet, coagulation, and fibrinolysis markers in patients with acute ischemic stroke, Semin. Thromb. Hemost. 23: 535-541 (1997).
	88.	VASAN, et al. Plasma Natriuretic Peptides for Community Screening for Left Ventricular Hypertrophy and Systolic Dysfunction. JAMA. 2002;288(10): 1252-1259.

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND PEPs OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/714,078
				Filing Date	November 14, 2003
				First Named Inventor	Gunars Valkirs
				Art Unit	1641
				Examiner Name	Lisa V. Cook
Sheet	7	Of	7	Attorney Docket Number	36671-743.503

NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	89.	VASAN, R. S. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006 May 16;113(19):2335-62.
	90.	ZHOU, et al. HBO suppresses Nogo-A, Ng-R, or RhoA expression in the cerebral cortex after global ischemia. Biochem Biophys Res Commun. 2003 Sep 19;309(2):368-76.
	91.	ZWEIG, et al. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993 Apr;39(4):561-77.

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*